Cancer Immunology, Immunotherapy 3/2020

nach oben

Inhaltsverzeichnis ( 17 Artikel )

01.03.2020 | Review | Ausgabe 3/2020 Open Access

The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer

Akshay J. Patel, Alex Richter, Mark T. Drayson, Gary W. Middleton

PDF-Version jetzt herunterladen Zum Volltext

21.12.2019 | Original Article | Ausgabe 3/2020

The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies

Brooke E. Wilson, Bertrand Routy, Adnan Nagrial, Venessa T. Chin

31.12.2019 | Original Article | Ausgabe 3/2020 Open Access

Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer

Simer J. Bains, Hanna Abrahamsson, Kjersti Flatmark, Svein Dueland, Knut H. Hole, Therese Seierstad, Kathrine Røe Redalen, Sebastian Meltzer, Anne Hansen Ree

PDF-Version jetzt herunterladen Zum Volltext

01.03.2020 | Original Article | Ausgabe 3/2020

Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients

Junxun Ma, Danyang Sun, Jinliang Wang, Chun Han, Yuanyu Qian, Guangying Chen, Xiaoyan Li, Juan Zhang, Pengfei Cui, Wushuang Du, Zhaozhen Wu, Shixue Chen, Xuan Zheng, Zhichao Yue, Jia Song, Chan Gao, Shangli Cai, Yi Hu

02.01.2020 | Original Article | Ausgabe 3/2020

Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment

Pazit Salamon, Yoseph A. Mekori, Irit Shefler

03.01.2020 | Original Article | Ausgabe 3/2020

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Alessandra Battaglia, Alexia Buzzonetti, Marco Fossati, Giovanni Scambia, Andrea Fattorossi, Madi R. Madiyalakan, Yolanda D. Mahnke, Christopher Nicodemus

06.01.2020 | Original Article | Ausgabe 3/2020

Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study

Guowei Zhang, Ruirui Cheng, Huijuan Wang, Yong Zhang, Xiangtao Yan, Peng Li, Mina Zhang, Xiaojuan Zhang, Jinpo Yang, Yuanyuan Niu, Zhiyong Ma

01.03.2020 | Original Article | Ausgabe 3/2020

Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas

Mikael Roussel, Faustine Lhomme, Caroline E. Roe, Todd Bartkowiak, Pauline Gravelle, Camille Laurent, Thierry Fest, Jonathan M. Irish

09.01.2020 | Original Article | Ausgabe 3/2020

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

Subhashis Sarkar, Sachin K. S. Chauhan, John Daly, Alessandro Natoni, Heather Fairfield, Robert Henderson, Emma Nolan, Dawn Swan, Jinsong Hu, Michaela R. Reagan, Michael O’Dwyer

01.03.2020 | Original Article | Ausgabe 3/2020 Open Access

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

Caroline Bergenfelz, Anna Roxå, Meliha Mehmeti, Karin Leandersson, Anna-Maria Larsson

PDF-Version jetzt herunterladen Zum Volltext

13.01.2020 | Original Article | Ausgabe 3/2020 Open Access

Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy

Remy Thomas, Hibah Shaath, Adviti Naik, Salman M. Toor, Eyad Elkord, Julie Decock

PDF-Version jetzt herunterladen Zum Volltext

16.01.2020 | Original Article | Ausgabe 3/2020

The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction

Hongzhi Quan, Zhongyan Shan, Ziyi Liu, Sixuan Liu, Liu Yang, Xiaodan Fang, Kun Li, Baisheng Wang, Zhiyuan Deng, Yanjia Hu, Zhigang Yao, Junhui Huang, Jianjun Yu, Kun Xia, Zhangui Tang, Liangjuan Fang

24.01.2020 | Clinical Trial Report | Ausgabe 3/2020 Open Access

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

Steve Boudewijns, Martine Bloemendal, Nienke de Haas, Harm Westdorp, Kalijn F. Bol, Gerty Schreibelt, Erik H. J. G. Aarntzen, W. Joost Lesterhuis, Mark A. J. Gorris, Alexandra Croockewit, Lieke L. van der Woude, Michelle M. van Rossum, Marieke Welzen, Anna de Goede, Stanleyson V. Hato, Winette T. A. van der Graaf, Cornelis J. A. Punt, Rutger H. T. Koornstra, Winald R. Gerritsen, Carl G. Figdor, I. Jolanda M. de Vries

PDF-Version jetzt herunterladen Zum Volltext

05.12.2019 | Letter to the Editors | Ausgabe 3/2020

PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab

Pengfei Li, Guowei Che

14.01.2020 | Letter to the Editors | Ausgabe 3/2020

PCSK9 is a promising prognostic marker in patients with advanced NSCLC

Aldo Bonaventura, Francesco Grossi, Fabrizio Montecucco

24.01.2020 | Retraction Note | Ausgabe 3/2020

Retraction Note to: Bio‑HMGB1 from breast cancer contributes to M‑MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC‑like cells

Zhaoliang Su, Ping Ni, Peng She, Yueqin Liu, Seidu A. Richard, Wenlin Xu, Haitao Zhu, Jia Wang

18.02.2020 | Acknowledgement | Ausgabe 3/2020

Acknowledgement to reviewers

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

28.05.2020 | Ösophaguskarzinom | Nachrichten

Newsletter bestellen

Bildnachweise

Mail Icon II

Cancer Immunology, Immunotherapy

Ausgabe 3/2020

Inhaltsverzeichnis ( 17 Artikel )

The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer

The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies

Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer

Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients

Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study

Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy

The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab

PCSK9 is a promising prognostic marker in patients with advanced NSCLC

Retraction Note to: Bio‑HMGB1 from breast cancer contributes to M‑MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC‑like cells

Acknowledgement to reviewers

Ausgabe 6/2020

Ausgabe 5/2020

Ausgabe 4/2020

Ausgabe 3/2020

Ausgabe 2/2020

Ausgabe 1/2020

Ausgabe 12/2019

Ausgabe 11/2019

Ausgabe 10/2019

Ausgabe 9/2019

Eine Option für die zweite Linie beim Ösophagus-Ca.

Selbst große Gallenblasenpolypen nur selten maligne

Vorteil für Checkpointhemmer bei MGMT-positivem Glioblastom?

Jens Spahn lockert Vorschriften für Corona-Tests

Newsletter

Springer Medizin

Inhaltsverzeichnis ( 17 Artikel )

The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer

The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies

Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer

Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients

Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study

Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy

The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab

PCSK9 is a promising prognostic marker in patients with advanced NSCLC

Retraction Note to: Bio‑HMGB1 from breast cancer contributes to M‑MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC‑like cells

Acknowledgement to reviewers

Aktuelle Ausgaben

Ausgabe 6/2020

Ausgabe 5/2020

Ausgabe 4/2020

Ausgabe 3/2020

Ausgabe 2/2020

Ausgabe 1/2020

Ausgabe 12/2019

Ausgabe 11/2019

Ausgabe 10/2019

Ausgabe 9/2019

Neu im Fachgebiet Onkologie

Eine Option für die zweite Linie beim Ösophagus-Ca.

Selbst große Gallenblasenpolypen nur selten maligne

Vorteil für Checkpointhemmer bei MGMT-positivem Glioblastom?

Jens Spahn lockert Vorschriften für Corona-Tests

Newsletter